Cargando…

Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies

Patients suffering from acute myeloid leukemias (AML) bearing FMS-like tyrosine kinase-3-internal tandem duplications (FLT3-ITD) have poor outcomes following cytarabine- and anthracyclin-based induction therapy. To a major part this is attributed to drug resistance of FLT3-ITD-positive leukemic cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kasper, S, Breitenbuecher, F, Heidel, F, Hoffarth, S, Markova, B, Schuler, M, Fischer, T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3317524/ https://www.ncbi.nlm.nih.gov/pubmed/22829255 http://dx.doi.org/10.1038/bcj.2012.5

Ejemplares similares

Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells
por: Metts, Jonathan, et al.
Publicado: (2017)

The GSK3β/Mcl-1 axis is regulated by both FLT3-ITD and Axl and determines the apoptosis induction abilities of FLT3-ITD inhibitors
por: Qiu, Yang, et al.
Publicado: (2023)

Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance
por: Fleischmann, Maximilian, et al.
Publicado: (2021)

Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD(+) acute myeloid leukemia
por: Li, Dan, et al.
Publicado: (2020)

How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia
por: Haage, Tobias R., et al.
Publicado: (2023)

SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia
por: van der Werf, Inge, et al.
Publicado: (2021)

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia
por: Pillinger, Genevra, et al.
Publicado: (2015)

DOCK2: A novel FLT3/ITD leukemia drug target
por: Wu, Min, et al.
Publicado: (2017)

Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia
por: Burchert, Andreas
Publicado: (2021)

Arsenic trioxide induces autophagic degradation of the FLT3-ITD mutated protein in FLT3-ITD acute myeloid leukemia cells
por: Liu, Xiao-Jian, et al.
Publicado: (2020)

RUNX1 cooperates with FLT3-ITD to induce leukemia
por: Behrens, Kira, et al.
Publicado: (2017)

Prolonged cellular midostaurin retention suggests potential alternative dosing strategies for FLT3-ITD-positive leukemias
por: Lipka, D B, et al.
Publicado: (2016)

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
por: Wang, Aoli, et al.
Publicado: (2016)

Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
por: Iannotta, R., et al.
Publicado: (2022)

Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification
por: Tian, Tian, et al.
Publicado: (2019)

MicroRNA networks in FLT3-ITD acute myeloid leukemia
por: Hoang, Dinh Hoa, et al.
Publicado: (2022)

Lack of FLT3-ITD in Tunisian childhood acute lymphoblastic leukemia
por: Frikha, Rim, et al.
Publicado: (2022)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models
por: Mali, Raghuveer Singh, et al.
Publicado: (2020)

Novel AXL-targeted agents overcome FLT3 inhibitor resistance in FLT3-ITD(+) acute myeloid leukemia cells
por: Liu, Yi, et al.
Publicado: (2021)

Selectively targeting FLT3-ITD mutants over FLT3- wt by a novel inhibitor for acute myeloid leukemia
por: Wang, Aoli, et al.
Publicado: (2020)

The sensitivity of the FLT3-ITD detection method is an important consideration when diagnosing acute myeloid leukemia
por: Sakaguchi, Masahiro, et al.
Publicado: (2020)

Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia
por: He, Bai‐Liang, et al.
Publicado: (2020)

CD52 is a novel target for the treatment of FLT3-ITD-mutated myeloid leukemia
por: Karnan, Sivasundaram, et al.
Publicado: (2021)

Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD(+) Acute Myeloid Leukemia
por: Bregante, Javier, et al.
Publicado: (2021)

CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML
por: Waldeck, Silvia, et al.
Publicado: (2020)

Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3
por: Nagai, Kozo, et al.
Publicado: (2018)

FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia
por: Fang, Douglas D., et al.
Publicado: (2021)

Expression of protein-tyrosine phosphatases in Acute Myeloid Leukemia cells: FLT3 ITD sustains high levels of DUSP6 expression
por: Arora, Deepika, et al.
Publicado: (2012)

FLT3/ITD associated with an immature immunophenotype in PML-RARα leukemia
por: Takenokuchi, Mariko, et al.
Publicado: (2012)

Feature genes predicting the FLT3/ITD mutation in acute myeloid leukemia
por: LI, CHENGLONG, et al.
Publicado: (2016)

Gab2 is Essential for Transformation by FLT3-ITD in Acute Myeloid Leukemia
por: Sies, Katharina, et al.
Publicado: (2019)

FLT3-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk Stratification
por: Li, Andrew Y., et al.
Publicado: (2021)

Synergistic killing of FLT3ITD-positive AML cells by combined inhibition of tyrosine-kinase activity and N-glycosylation
por: Tsitsipatis, Dimitrios, et al.
Publicado: (2017)

A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia
por: Lee, Lauren Y., et al.
Publicado: (2021)

Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
por: Xu, Dan, et al.
Publicado: (2022)

Targeting chaperon protein HSP70 as a novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia
por: Hu, Chen, et al.
Publicado: (2021)

Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature
por: Wolleschak, Denise, et al.
Publicado: (2013)

Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field
por: Duminuco, Andrea, et al.
Publicado: (2022)

miR-451a abrogates treatment resistance in FLT3-ITD-positive acute myeloid leukemia
por: Krakowsky, Rosanna H. E., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jgiu5meedmjta3thtkd2rkndqu